Camptothecin

• 

  Subject Areas on Research

  • 9-Nitrocamptothecin as second line chemotherapy for men with progressive, metastatic, hormone refractory prostate cancer: Results of the CALGB 99901. 
  • A Phase I study of escalating doses of the tyrosine kinase inhibitor semaxanib (SU5416) in combination with irinotecan in patients with advanced colorectal carcinoma. 
  • A change in the apparent diffusion coefficient after treatment with bevacizumab is associated with decreased survival in patients with recurrent glioblastoma multiforme. 
  • A phase 1 dose-escalation study of veliparib with bimonthly FOLFIRI in patients with advanced solid tumours. 
  • A phase I trial of olanzapine (Zyprexa) for the prevention of delayed emesis in cancer patients: a Hoosier Oncology Group study. 
  • A phase II single-arm study of irinotecan in combination with temozolomide (TEMIRI) in children with newly diagnosed high grade glioma: a joint ITCC and SIOPE-brain tumour study. 
  • A phase II study of docetaxel-irinotecan combination in advanced pancreatic cancer. 
  • A randomised, double-blind, placebo-controlled multi-centre phase III trial of XELIRI/FOLFIRI plus simvastatin for patients with metastatic colorectal cancer. 
  • Activity of 9-dimethylaminomethyl-10-hydroxycamptothecin against pediatric and adult central nervous system tumor xenografts. 
  • Adding pharmacogenetics information to drug labels: lessons learned. 
  • Addition of bevacizumab to fluorouracil-based first-line treatment of metastatic colorectal cancer: pooled analysis of cohorts of older patients from two randomized clinical trials. 
  • Addition of bevacizumab to irinotecan- and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases. 
  • Addition of bevacizumab to standard radiation therapy and daily temozolomide is associated with minimal toxicity in newly diagnosed glioblastoma multiforme. 
  • Alternate statistical tools and limitations in genetic marker association studies in single-arm drug cancer trials. 
  • Analysis of cleavage complexes using reactive inhibitor derivatives. 
  • Anti proliferative activity of ELACY (CP-4055) in combination with cloretazine (VNP40101M), idarubicin, gemcitabine, irinotecan and topotecan in human leukemia and lymphoma cells. 
  • Antitumor activity of temozolomide combined with irinotecan is partly independent of O6-methylguanine-DNA methyltransferase and mismatch repair phenotypes in xenograft models. 
  • Apoptotic capacity and risk of squamous cell carcinoma of the head and neck. 
  • Aspirin and COX-2 inhibitor use in patients with stage III colon cancer. 
  • Avastin: more questions than answers. . . 
  • BACPTDP: a water-soluble camptothecin pro-drug with enhanced activity in hypoxic/acidic tumors. 
  • Bevacizumab (BVZ)-associated toxicities in children with recurrent central nervous system tumors treated with BVZ and irinotecan (CPT-11): a Pediatric Brain Tumor Consortium Study (PBTC-022). 
  • Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. 
  • Bevacizumab combined with standard fluoropyrimidine-based chemotherapy regimens to treat colorectal cancer. 
  • Bevacizumab improves the overall and progression-free survival of patients with metastatic colorectal cancer treated with 5-fluorouracil-based regimens irrespective of baseline risk. 
  • Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas. 
  • Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. 
  • Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. 
  • CALGB 80403 (Alliance)/E1206: A Randomized Phase II Study of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction Cancers. 
  • Camptothecin analogs with enhanced activity against human breast cancer cells. I. Correlation of potency with lipophilicity and persistence in the cleavage complex. 
  • Camptothecin analogs with enhanced activity against human breast cancer cells. II. Impact of the tumor pH gradient. 
  • Camptothecin analogues with enhanced antitumor activity at acidic pH. 
  • Camptothecin and Fas receptor agonists synergistically induce medulloblastoma cell death: ROS-dependent mechanisms. 
  • Cancer and Leukemia Group B/Southwest Oncology Group trial 80405: a phase III trial of chemotherapy and biologics for patients with untreated advanced colorectal adenocarcinoma. 
  • Capecitabine plus oxaliplatin vs infusional 5-fluorouracil plus oxaliplatin in the treatment of colorectal cancer. Pro: The CapeOx regimen is preferred over FOLFOX. 
  • Cetuximab plus cisplatin, irinotecan, and thoracic radiotherapy as definitive treatment for locally advanced, unresectable esophageal cancer: a phase-II study of the SWOG (S0414). 
  • Chemoradiotherapy for locoregionally advanced squamous cell carcinoma of the base of tongue. 
  • Chemotherapeutic and biologic agents as radiosensitizers in rectal cancer. 
  • Cisplatin versus carboplatin-based regimens for the treatment of patients with metastatic lung cancer. An analysis of Veterans Health Administration data. 
  • Cisplatin, irinotecan, and bevacizumab for untreated extensive-stage small-cell lung cancer: CALGB 30306, a phase II study. 
  • Colon cancer, version 3.2014. 
  • Combined coagulation phase-directed factor Xa inhibition with heparin compounds and DX-9065a - a direct and selective antagonist. 
  • Combined modality treatment for rectal cancer. 
  • Combined-modality therapy for rectal cancer: future prospects. 
  • Comparison of adjuvant systemic chemotherapy with or without hepatic arterial infusional chemotherapy after hepatic resection for metastatic colorectal cancer. 
  • Comparison of in vitro activities of camptothecin and nitidine derivatives against fungal and cancer cells. 
  • Complex response of breast epithelial cell lines to topoisomerase inhibitors. 
  • Correlation of MRI sequences to assess progressive glioblastoma multiforme treated with bevacizumab. 
  • CpG island methylator phenotype is associated with response to adjuvant irinotecan-based therapy for stage III colon cancer. 
  • Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis: outcomes from a single tertiary institution. 
  • DNA strand breaks: the DNA template alterations that trigger p53-dependent DNA damage response pathways. 
  • Dual inhibition of epidermal growth factor receptor and vascular endothelial growth factor receptor phosphorylation by AEE788 reduces growth and metastasis of human colon carcinoma in an orthotopic nude mouse model. 
  • Dual role of glutathione in modulating camptothecin activity: depletion potentiates activity, but conjugation enhances the stability of the topoisomerase I-DNA cleavage complex. 
  • Dynamic susceptibility contrast MRI measures of relative cerebral blood volume as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 multicenter trial. 
  • Early dissemination of bevacizumab for advanced colorectal cancer: a prospective cohort study. 
  • Early post-bevacizumab progression on contrast-enhanced MRI as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 Central Reader Study. 
  • Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial. 
  • Effects of 10-hydroxycamptothecin, delivered from locally injectable poly(lactide-co-glycolide) microspheres, in a murine human oral squamous cell carcinoma regression model. 
  • Effects of camptothecin or TOP1 overexpression on genetic stability in Saccharomyces cerevisiae. 
  • Efficacy endpoints of radiation therapy group protocol 0247: a randomized, phase 2 study of neoadjuvant radiation therapy plus concurrent capecitabine and irinotecan or capecitabine and oxaliplatin for patients with locally advanced rectal cancer. 
  • Efficacy of bevacizumab plus irinotecan in children with recurrent low-grade gliomas--a Pediatric Brain Tumor Consortium study. 
  • Efficacy of the nanoparticle-drug conjugate CRLX101 in combination with bevacizumab in metastatic renal cell carcinoma: results of an investigator-initiated phase I-IIa clinical trial. 
  • Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. 
  • Elevated DNA polymerase alpha, DNA polymerase beta, and DNA topoisomerase II in a melphalan-resistant rhabdomyosarcoma xenograft that is cross-resistant to nitrosoureas and topotecan. 
  • Enhancement of irinotecan (CPT-11) activity against central nervous system tumor xenografts by alkylating agents. 
  • Enterohepatic recirculation model of irinotecan (CPT-11) and metabolite pharmacokinetics in patients with glioma. 
  • Experience with irinotecan for the treatment of malignant glioma. 
  • Extending principles learned in model systems to clinical trials design. 
  • FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. 
  • Five hundred patients with Merkel cell carcinoma evaluated at a single institution. 
  • Genome-destabilizing effects associated with top1 loss or accumulation of top1 cleavage complexes in yeast. 
  • Glioblastoma in the elderly: the effect of aggressive and modern therapies on survival. 
  • Health-related quality of life impact of bevacizumab when combined with irinotecan, 5-fluorouracil, and leucovorin or 5-fluorouracil and leucovorin for metastatic colorectal cancer. 
  • High-dose, single-agent irinotecan as first-line therapy in the treatment of metastatic colorectal cancer. 
  • ISG15 as a novel tumor biomarker for drug sensitivity. 
  • Irinotecan for malignant mesothelioma A phase II trial by the Cancer and Leukemia Group B. 
  • Irinotecan plus cisplatin in patients with advanced non-small-cell lung cancer. 
  • Irinotecan therapy in adults with recurrent or progressive malignant glioma. 
  • Irinotecan treatment for recurrent malignant glioma using an every-3-week regimen. 
  • Irinotecan: promising activity in the treatment of malignant glioma. 
  • KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803. 
  • Lack of efficacy of bevacizumab + irinotecan in cases of pediatric recurrent ependymoma--a Pediatric Brain Tumor Consortium study. 
  • Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a Pediatric Brain Tumor Consortium study. 
  • Long-term outcome of concurrent chemotherapy and reirradiation for recurrent and second primary head-and-neck squamous cell carcinoma. 
  • Loss of a p53-associated G1 checkpoint does not decrease cell survival following DNA damage. 
  • MRE11-deficiency associated with improved long-term disease free survival and overall survival in a subset of stage III colon cancer patients in randomized CALGB 89803 trial. 
  • Magnetic resonance spectroscopy as an early indicator of response to anti-angiogenic therapy in patients with recurrent glioblastoma: RTOG 0625/ACRIN 6677. 
  • Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803. 
  • Modest advances in survival for patients with colorectal-associated peritoneal carcinomatosis in the era of modern chemotherapy. 
  • Modulation of pancreatic cancer chemoresistance by inhibition of TAK1. 
  • Molecular cloning of a cDNA of a camptothecin-resistant human DNA topoisomerase I and identification of mutation sites. 
  • Motesanib with or without panitumumab plus FOLFIRI or FOLFOX for the treatment of metastatic colorectal cancer. 
  • Multiagent chemotherapy for isolated colorectal liver metastases: a single-centered retrospective study. 
  • Mutagenic processing of ribonucleotides in DNA by yeast topoisomerase I. 
  • Neoadjuvant chemoradiation for distal rectal cancer: 5-year updated results of a randomized phase 2 study of neoadjuvant combined modality chemoradiation for distal rectal cancer. 
  • New combinations in metastatic colorectal cancer: what are our expectations? 
  • O6-benzylguanine-mediated enhancement of chemotherapy. 
  • Pathologic response to preoperative chemotherapy in colorectal liver metastases: fibrosis, not necrosis, predicts outcome. 
  • Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. 
  • Phase 1 trial of irinotecan plus BCNU in patients with progressive or recurrent malignant glioma. 
  • Phase 1 trial of temozolomide plus irinotecan plus O6-benzylguanine in adults with recurrent malignant glioma. 
  • Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy. 
  • Phase 2 trial of BCNU plus irinotecan in adults with malignant glioma. 
  • Phase I and pharmacokinetic study of gimatecan given orally once a week for 3 of 4 weeks in patients with advanced solid tumors. 
  • Phase I and pharmacological study of oral 9-aminocamptothecin colloidal dispersion (NSC 603071) in patients with advanced solid tumors. 
  • Phase I clinical and pharmacology study of topotecan given daily for 5 consecutive days to patients with advanced solid tumors, with attempt at dose intensification using recombinant granulocyte colony-stimulating factor. 
  • Phase I dose escalation study of gemcitabine plus irinotecan in advanced solid tumors. 
  • Phase I evaluation of prolonged-infusion gemcitabine with irinotecan for relapsed or refractory leukemia or lymphoma. 
  • Phase I study of 9-nitro-20(S)-camptothecin in combination with cisplatin for patients with advanced malignancies. 
  • Phase I study of concomitant chemoradiotherapy with irinotecan, 5-FU, and hydroxyurea for patients with advanced and/or recurrent head and neck cancer. 
  • Phase I study of sunitinib and irinotecan for patients with recurrent malignant glioma. 
  • Phase I trial and pharmacokinetic (PK) and pharmacodynamics (PD) study of topotecan using a five-day course in children with refractory solid tumors: a pediatric oncology group study. 
  • Phase I trial of combined irinotecan and oxaliplatin given every three weeks to patients with metastatic colorectal cancer. 
  • Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma. 
  • Phase I trial of systemic oxaliplatin combination chemotherapy with hepatic arterial infusion in patients with unresectable liver metastases from colorectal cancer. 
  • Phase II Trial of Upfront Bevacizumab, Irinotecan, and Temozolomide for Unresectable Glioblastoma. 
  • Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma. 
  • Phase II study of carboplatin, irinotecan, and thalidomide combination in patients with extensive stage small-cell lung cancer. 
  • Phase II study of induction cisplatin and irinotecan followed by concurrent carboplatin, etoposide, and thoracic radiotherapy for limited-stage small-cell lung cancer, CALGB 30206. 
  • Phase II study of irinotecan (CPT-11) in children with high-risk malignant brain tumors: the Duke experience. 
  • Phase II study of irinotecan plus cisplatin in patients with advanced non-small-cell lung cancer. 
  • Phase II trial of 9-aminocamptothecin (NSC 603071) administered as a 120-hr continuous infusion weekly for three weeks in metastatic colorectal carcinoma. 
  • Phase II trial of 9-aminocamptothecin administered as a 72-hour continuous infusion in metastatic colorectal carcinoma. 
  • Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. 
  • Phase II trial of gemcitabine plus irinotecan in patients with esophageal cancer: a Southwest Oncology Group (SWOG) trial. 
  • Phase II trial of hepatic artery infusional and systemic chemotherapy for patients with unresectable hepatic metastases from colorectal cancer: conversion to resection and long-term outcomes. 
  • Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. 
  • Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma. 
  • Phase II trial of irinotecan/gemcitabine as second-line therapy for relapsed and refractory small-cell lung cancer: Cancer and Leukemia Group B Study 39902. 
  • Phase II trial of karenitecin in patients with relapsed or refractory non-small cell lung cancer (CALGB 30004). 
  • Phase II trial of temozolomide (TMZ) plus irinotecan (CPT-11) in adults with newly diagnosed glioblastoma multiforme before radiotherapy. 
  • Polyploidy induction as a consequence of topoisomerase inhibition. A flow cytometric assessment. 
  • Pre-clinical evaluation of SN-38 and novel camptothecin analogs against human chronic B-cell lymphocytic leukemia lymphocytes. 
  • Preclinical evaluation of gemcitabine combination regimens for application in acute myeloid leukemia. 
  • Predictive and prognostic analysis of PIK3CA mutation in stage III colon cancer intergroup trial. 
  • Preoperative chemotherapy and the risk of hepatotoxicity and morbidity after liver resection for metastatic colorectal cancer: a single institution experience. 
  • Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer. 
  • Prospective phase II trial of combination hepatic artery infusion and systemic chemotherapy for unresectable colorectal liver metastases: Long term results and curative potential. 
  • Radiation Therapy Oncology Group 0247: a randomized Phase II study of neoadjuvant capecitabine and irinotecan or capecitabine and oxaliplatin with concurrent radiotherapy for patients with locally advanced rectal cancer. 
  • Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904. 
  • Randomized phase II study of neoadjuvant combined-modality chemoradiation for distal rectal cancer: Radiation Therapy Oncology Group Trial 0012. 
  • Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study. 
  • Randomized phase II trial of gemcitabine plus irinotecan or docetaxel in stage IIIB or stage IV NSCLC. 
  • Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer. 
  • Recommendation for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancer. 
  • Release of DNA from dead and dying lymphocyte and monocyte cell lines in vitro. 
  • Response-independent survival benefit in metastatic colorectal cancer: a comparative analysis of N9741 and AVF2107. 
  • Ring-opening polymerization of prodrugs: a versatile approach to prepare well-defined drug-loaded nanoparticles. 
  • Schedule-dependent activity of irinotecan plus BCNU against malignant glioma xenografts. 
  • Schedule-dependent activity of temozolomide plus CPT-11 against a human central nervous system tumor-derived xenograft. 
  • Successful clinical response to irinotecan in desmoplastic round blue cell tumor. 
  • Synergistic cytotoxicity with 2'-deoxy-5-azacytidine and topotecan in vitro and in vivo. 
  • TBCRC 018: phase II study of iniparib in combination with irinotecan to treat progressive triple negative breast cancer brain metastases. 
  • Targeted therapy in rectal cancer. 
  • Targeting methylguanine-DNA methyltransferase in the treatment of neuroblastoma. 
  • The activity of camptothecin analogues is enhanced in histocultures of human tumors and human tumor xenografts by modulation of extracellular pH. 
  • The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma. 
  • The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of K-ras mutation status: analysis of a phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer. 
  • The emerging role of irinotecan (CPT-11) in the treatment of malignant glioma in brain tumors. 
  • The extracellular release of HMGB1 during apoptotic cell death. 
  • The impact of tumor physiology on camptothecin-based drug development. 
  • The role of targeted therapy in the treatment of colorectal cancer. 
  • The treatment of colorectal carcinoma: standard chemotherapy and beyond. 
  • Therapeutic activity of 7-[(2-trimethylsilyl)ethyl)]-20 (S)-camptothecin against central nervous system tumor-derived xenografts in athymic mice. 
  • Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against pediatric and adult central nervous system tumor xenografts. 
  • Topoisomerase I is essential in Cryptococcus neoformans: role In pathobiology and as an antifungal target. 
  • Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia. 
  • Treatment of High-Grade Metastatic Pancreatic Neuroendocrine Carcinoma with FOLFIRINOX. 
  • Treatment of central nervous system xenografts with camptothecins. 
  • Treatment of neoplastic meningitis with intrathecal 9-nitro-camptothecin. 
  • Treatment patterns and clinical outcomes in patients with metastatic colorectal cancer initially treated with FOLFOX-bevacizumab or FOLFIRI-bevacizumab: results from ARIES, a bevacizumab observational cohort study. 
  • Trex2 enables spontaneous sister chromatid exchanges without facilitating DNA double-strand break repair. 
  • Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan. 
  • Tumor lysis syndrome and acute renal failure after treatment of non-small-cell lung carcinoma with combination irinotecan and cisplatin. 
  • Tumor physiology and charge dynamics of anticancer drugs: implications for camptothecin-based drug development. 
  • Two distinct mechanisms of Topoisomerase 1-dependent mutagenesis in yeast. 
  • Two studies evaluating irinotecan treatment for recurrent malignant glioma using an every-3-week regimen. 
  • Unresectable intrahepatic cholangiocarcinoma: Systemic plus hepatic arterial infusion chemotherapy is associated with longer survival in comparison with systemic chemotherapy alone. 
  • Updated long-term survival for patients with metastatic colorectal cancer treated with liver resection followed by hepatic arterial infusion and systemic chemotherapy. 
  • [Bevacizumab/irinotecan. An active treatment for recurrent high grade gliomas: preliminary results of an ANOCEF Multicenter Study]. 
• 

  Keywords of People

  • Grambow, Steven C., Assistant Professor of Biostatistics and Bioinformatics, Biostatistics & Bioinformatics
  • Pang, Herbert, Adjunct Assistant Professor in the Department of Biostatistics and Bioinformatics, Biostatistics & Bioinformatics
  • Sampson, John Howard, Robert H., M.D. and Gloria Wilkins Professor of Neurosurgery, in the School of Medicine, Immunology